

This is a Platinum Open Access Journal distributed under the terms of the Creative Commons Attribution Non-Commercial License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Improved COVID-19 testing by extraction-free SARS-CoV-2 RT-PCR

Khelil Mohamed Mokhtar

Pasteur Institute of Algeria, Department of Immunology, Annex of M'sila, Algeria

ARTICLE INFO

Corresponding author:

Khelil Mohamed Mokhtar Pasteur Institute of Algeria Department of Immunology Annex of M'sila Algeria

Phone: +213781032119 E-mail: kh.immuno@gmail.com

Key words:

SARS-CoV-2, COVID-19, RT-PCR, heat treatment, nasopharyngeal swab samples

LETTER TO THE EDITOR

The RNA extraction is an important checkpoint for the detection of SARS-CoV-2 in swab samples, but it is a major barrier to available and rapid COVID-19 testing. In this study, we validated the extraction-free RT-qPCR method by heat-treatment as an accurate option to nucleic acid purification in Algerian population.

Dear editor,

The new emergence of the novel human coronavirus, in December 2019, in Wuhan City (China), rapidly evolved into a global pandemic. The virus was confirmed to have spread to Algeria in February 2020, which put notable pressure on public and private health laboratories as they attempt to keep up with demands for SARSCoV-2 testing despite shortage of reagents (1). Currently, the widely used protocol for SARS-CoV-2 detection is RT-qPCR assay preceded by purification of viral RNA from patient sample, typically from nasopharyngeal (NP) swab as described by CDC and WHO (2-4). However, nucleic acid purification step is not only laborious and time-consuming, but the additional steps requiring manual handling can result in experimental errors, especially false positive results due to specimen-to-specimen carryover (5). To address this issue, recent attempts have been made to circumvent RNA extraction in COVID-19 testing by performing RTqPCR directly on heat-treated subject samples (65°C for 30 min or 95°C for 10min) or directly loading patient swab medium into RT-PCR reaction mix. Using heat-treatment approach the sensitivity ranged from 92 to 96% and specificity from 93 to 100% (6). Here, we tested the direct method of SARS-CoV-2 RT-qPCR on heat-treated (Hit-RT-PCR) nasopharyngeal swab samples and compared the results with RNA-extraction based RT-PCR results.

This study was conducted at the clinical laboratory of Institut Pasteur of M'sila, Algeria. Nasopharyngeal swabs (NP) from patients with high likelihood for COVID-19 were collected by medical infectiologists and deposited in viral transport medium at different healthcare institution of the city of M'sila. Arrived to the laboratory, samples were stored at -20°C until extracted and tested within 72h. For routine analysis, RNA was extracted from 140 μ L of NP samples using the QIAamp Viral RNA Mini kit. Reverse

transcription and quantitative PCR were performed using the Biogerm® novel Coronavirus (2019-nCoV) nucleic acid kit following the manufacturer instructions: Total reactions of 25µl were obtained by mixing 20µl of master mix (primers and probe mix: ORF1ab, N and RNase P genes) and 5 µl of clinical sample to fill the reaction. The thermal cycling steps were: stage1: 50°C for 10 min, stage2: 95°C for 5 min, stage3: 95°C for 10 sec, 55°C for 40 sec, 40 cycles. The RT-qPCR was performed on a Rotor-Gen Q real time PCR machine (Qiagen®) using the Rotor-Gen Software v2.3.

We initially aimed to validate heat-treatment method to get an accurate view of its performance in a real world clinical diagnostic setting. We blindly heated a panel of aliquots from 60 NP samples representing intermediate (CT of 20 - 30) and low (CT of more than 30) viral RNA loads by direct RT-qPCR. The SARS-CoV-2 Ct levels (ORF1ab and N) in these samples were previously determined by RT-qPCR that included RNA extraction (Ct cutoff ≤38).

NP swab samples were thermally treated in water bath at 65° C for 30 min. Samples were then placed in room temperature for 15 min, vortexed for 10 seconds, centrifuged at 1000g for 1 min and 5µl of the supernatant was directly loaded into RT-qPCR reaction. Comparably, aliquots from 161 NP samples were subjected to heat-treatment but with increasing heating time to 60 min.

An agreement analysis (positive and negative percent agreement) were applied between diagnostic results of our experiment and results obtained by the conventional SARS-CoV-2 testing protocol. Diagnostic results were considered as categorical variables (1 for the presence of SARS cov2 infection and 0 for the absence of infection). All statistical analysis were performed using R version 3.6.0 (R Core Team, 2014) (7). In this work we used anonymized material from

samples that had been collected for clinical diagnostics of SARS-CoV-2.

We found a weak agreement when NP samples were heated for 30min (PPA: 58%, 95%CI: 45 to 69%). But, the agreement increased (PPA: 78%, 95%CI: 70 to 84%) when we increased the heating time to (60 min). We also found a substantial agreement between N gene results of extracted and heat-inactivated samples (overall agreement 78%, 95%CI 70 to 83%) but a weak agreement for ORF1ab gene (overall agreement 45%, 95%CI 37 to 52%). Ct values of N gene for hit-RTqPCR samples were higher than for RNA eluates of the same samples (mean difference =1.9 Ct). Surprisingly, three samples were identified as COVID-19 positive by 60 min heat-treatment RTqPCR (one sample positive for N and ORF1ab and two for only N) but were negative on extracted RNA. Figure 1 and 2 show the full results of this experiment while Table 1 provides a summary.

Clinical laboratories of the developing world are overwhelmed with COVID-19 testing demands. As a means to validate heat-treatment RT-PCR method in our clinical laboratory, we have shown that prior heating at 65°C for 30 min was less accurate compared to prior heating at 65°C for 60 min. Our observation were not corroborated by previous results which showed that prior heating at 65°C for 30 min was adequate to correctly identify 92 to 96% of screened samples. This could be explained by difference in the composition of viral transport medium used (Inhibitory agents from the swab and medium may inhibit RT-qPCR) or a mutations in the Algerian strain of SARS-cov2, rendering the virus more resistant to heat-treatment. Our improved protocol correctly identified 100% of clinical samples with viral load between (20 and 30 Ct). The only samples missed were those among lower Ct range (Ct> 30). Of the 2065 cases with a positive diagnosis at "Institut Pasteur of M'sila" by our clinical laboratory at the time of writing, only 27% would fall in this low Ct range, which demonstrate that our improved protocol will accurately detect the majority of COVID-19 patients. Evidence that analytical sensitivity of heat-treatment RT-PCR was inferior (higher Ct values) compared to extraction-based RT-qPCR is that heating for long time may degrade RNA in presence of metal ions and/or RNases and that more RNA was loaded for eluates compared to Hit-RT-PCR. Furthermore, the higher performance of primers and probes targeting short amplicon (N, 110 bp) confirmed previous reports. Hence, short amplicons targets may be more suitable for Hit-RT-qPCR protocol.

A surprising finding was that heat-treatment RT-PCR identified three samples as COVID-19 positive while they had been identified as COVID-19 negative by conventional protocol. The Ct values of heat-treatment RT-PCR samples were high (> 30) suggesting one possible explanation of this phenomenon: NP samples may had very low viral RNA load that was below the limit of detection - i.e the lowest concentration level with a detection rate of 95% for positive resultsof the RT-PCR kit (1000 copies/ml) (9). So, negative results in patients with typical symptoms of COVID-19 may become detectable by repeating the test. Unfortunately, we were unable to confirm COVID-19 positivity by collection of a new swab samples.

In summary, we have shown that screening for SARS-CoV-2 infection by RT-qPCR could be achieved through heat-treatment protocol (65°C for 60 min) without the use of RNA extraction kits, in the studied population. We hypothesize that each clinical laboratory should validate its own heat-treatment protocol which may be specific to the pre-analytical (viral transport medium composition) and environmental factors. Previous reports suggest that initial negative result by heat-treatment RT-PCR should be repeated by RNA extraction for: symptomatic patients, healthcare personnel, and others with a high suspicion of COVID-19 (8). However,

Figure 1	Heat-map of ORF1ab and N Ct values for (65°C, 30min) protocol
----------	---------------------------------------------------------------

9			map or		Tollo dire
	65°C,30)min	Eluate	Rnase	
ID	ORF1ab N		ORF1ab	P	
1	38	39	29	N 27	24
2	41	41	28	28	24
3	41	41	35	31	31
4	41	41	35	31	25
5	38	36	26	25	31
6	41	35	27	26	24
7	41	41	32	30	27
8	41	41	30	28	24
9	41	41	30	29	25
10	41	41	28	26	28
11	41	41	27	26	27
12	24	22	41	22	28
13	41	41	29	28	25
14	32	28	25	24	24
15	34	33	31	30	25
16	41	38	35	32	25
17	41	37	33	32	27
18	41	37	36	32	30
19	35	33	30	28	26
20	41	41	36	33	27
21	41	35	32	30	27
22	35	37	35	35	30
23	25	23	23	22	25
24	41	41	30	33	24
25	26	23	23	22	24
26	28	25	25	24	23
27	34	27	26	25	25
28	35	32	31	29	29
29	36	36	32	35	26
30	41	37	36	33	30
31	35	33	39	34	24
32	41	41	35	33	26
33	41	41	37	35	27
34	41	41	36	36	25
35	23	24	22	23	26
36	33	32	28	28	30
37	37	35	33	32	29
38	41	41	35	34	24
39	29	28	23	24	25
40	41	41	41	39	29
41	41	41	36	35	26

42	33	32	28	28	25
43	30	29	25	26	25
44	41	41	36	37	26
45	29	29	26	26	28
46	41	41	37	35	29
47	30	28	25	24	23
48	32	31	26	26	30
49	28	27	23	23	30
50	24	25	22	22	24
51	36	37	30	31	24
52	37	36	21	21	25
53	41	41	34	34	27
54	34	32	29	29	25
55	30	28	23	23	28
56	23	24	23	23	25
57	41	41	34	32	28
58	41	41	33	32	25
59	41	41	41	37	23
60	41	41	31	31	32

Figure 1. Heatmap of CT performed on 60 clinical samples using extracted RNA (ORF1ab, N) and hit-RT-PCR (65°C, 30min).

Control for RNA degradation by RT-PCR for RNase P transcripts in the same samples is shown on the right.

Figure 2 Heat-map of ORF1ab and N Ct values for (65°C, 60min) protocol

	65°C,60n	nin	Eluate	e	Danne	42	41	26	24	23	25	85	41	35	36	33	25
ID	ORF1ab	N	ORF1ab	N	Rnase P	43	41	26	24	25	25	86	41	41	36	33	25
1	34	27	27	28	24	44	41	26	25	25	26	87	41	41	41	41	27
2	41	35	32	31	24	45	41	35	33	33	28	88	31	25	27	26	33
3	41	34	35	34	31	46	41	38	36	36	29	89	35	29	27	26	26
4	41	36	36	35	25	47	41	22	22	22	23	90	41	35	34	32	27
5	32	27	33	32	31	48	41	36	30	30	32	91	41	32	31	29	27
6	28	24	23	24	24	49	41	41	36	34	30	92	27	23	22	22	30
7	41	32	32	32	27	50	41	36	38	36	24	93	41	38	41	35	25
8	27	23	23	23	24	51	41	32	32	31	24	94	41	32	31	29	24
9	26	22	23	23	25	52	41	22	22	22	25	95	41	23	22	21	24
10	41	31	30	30	28	53	41	23	22	22	27	96	41	37	35	31	23
11	30	24	24	24	27	54	41	41	34	34	25	97	41	35	26	27	25
12	29	23	24	24	28	55	41	24	24	24	28	98	41	29	36	34	29
13	41	33	33	32	25	56	41	33	32	32	25	99	41	27	24	24	26
14	37	30	28	29	24	57	41	36	36	36	28	100	33	28	27	26	35
15	41	41	41	41	25	58	41	27	26	25	25	101	34	28	27	26	24
16	41	41	41	41	25	59	41	37	38	38	23	102	41	31	29	27	26
17*	36	32	41	41	27	60	41	32	30	30	32	103	38	32	30	28	27
18	41	41	41	41	33	61	41	29	26	27	30	104	41	36	27	26	25
19*	41	34	41	41	26	62	41	23	34	34	24	105	41	23	22	22	26
20	41	31	41	36	27	63	34	29	25	24	23	106	41	41	37	35	30
21	41	32	31	32	27	64	32	26	26	23	25	107	41	41	41	41	29
22	32	27	41	37	30	65	38	29	26	25	33	108	41	38	36	35	24
23	41	41	31	31	25	66	41	38	41	33	30	109	41	41	41	41	25
24	41	30	27	27	24	67	41	28	25	24	30	110	41	22	22	22	29
25	41	34 23	35 23	33	24	68 60	38	32 28	27	26	30	111	41	22	22 22	22	26
26 27	28 27	29	28	23 28	23 25	69 70	41 41	41	25 41	34	31 25	112 113	41 41	29	34	23 34	25 25
28	41	36	33	33	29	70	41	41	41	41	24	113	41	41	35	35	26
29	41	30	25	23	26	72	41	33	29	29	24	115	41	41	38	36	28
30	41	36	33	33	30	73	33	26	24	23	31	116	25	24	22	23	29
31	41	41	41	41	24	74	41	38	41	35	25	117	41	41	41	36	23
32	41	39	41	41	26	75	41	31	34	32	31	118	41	41	41	41	32
33	30	28	26	26	27	76	41	41	37	33	24	119	41	41	41	41	30
34	41	41	41	41	25	77	41	41	37	34	27	120	30	25	24	23	24
35	41	41	41	36	26	78	36	33	29	28	24	121	30	25	24	23	24
36	41	41	41	37	30	79	41	41	41	41	25	122	34	29	25	25	25
37	41	41	41	41	29	80	41	41	41	36	28	123	33	31	28	27	27
38	41	30	28	28	24	81	41	31	31	30	27	124	41	41	36	36	25
39	41	41	41	38	25	82	41	33	36	34	28	125	41	36	37	35	28
40	41	37	41	37	29	83	41	33	37	35	25	126	31	29	25	25	25
41	41	30	29	29	26	84*	41	32	41	41	24	127	36	35	32	32	28
												-					

128	34	31	28	28	25
129	36	32	29	28	23
130	41	37	41	38	32
131	41	37	33	33	30
132	37	35	29	28	24
133	41	34	30	30	23
134	28	26	23	23	25
135	31	29	25	25	33
136	41	41	35	33	30
137	41	41	34	32	30
138	32	29	23	22	30
139	41	41	32	33	31
140	41	41	33	32	25
141	41	41	28	30	24
142	41	41	33	32	24
143	27	25	21	21	31
144	32	29	24	24	25
145	41	41	34	35	31
146	41	41	35	34	24
147	38	34	30	30	27
148	41	41	30	31	24
149	41	41	30	33	25
150	38	31	25	25	28
151	39	34	30	30	27
152	41	36	29	29	28
153	38	29	24	24	25
154	41	41	30	33	24
155	41	41	31	32	25
156	41	41	35	35	25
157	41	41	26	35	27
158	41	41	35	33	33
159	41	41	35	34	26
160	27	25	21	21	27
161	28	26	23	23	27

Figure 2. Heatmap of CT performed on 161 clinical samples using extracted RNA (ORF1ab, N) and hit-RT-PCR (65°C, 60min).

Control for RNA degradation by RT-PCR for RNase P transcripts in the same samples is shown on the right.

Three samples, marked with asterisk, negative in extraction-based routine diagnosis but positive by hit-RT-PCR.

Table 1 Detection sensitivity of Hit- RT-qPCR for 30 min versus Hit- RT-qPCR for 60 min on NP samples containing a range of SARS-CoV-2 viral RNA loads

Viral RNA load (Ct)	Heat-inactivation time					
	30 min	60 min				
20 - 30	26/34 (76%)	74/74 (100%)				
>30	9/26 (34%)	38/70 (54%)				
Total	35/60 (58%)	112/144 (78%)				

based on recent evidence showing the oddity of SARS-CoV-2 that can be cultured in respiratory samples 9 days after symptom onset, notably in patients with mild disease, it appears that retesting in such patients may not be necessary (10). Such a strategy would drastically reduce the need for RNA extraction for a substantial portion of future COVID-19 tests.



Acknowledgements

We are grateful to Mekki Oussama who participated in sample handling, organization and performed experiments.



REFERENCES

- 1. Taipale J. and Linnarsson S. To stop COVID-19, test everyone, repeatedly. Medium (2020). Available: at https://medium.com/@sten.linnarsson/to-stop-covid-19-test-everyone-373fd80eb03b.
- 2. Centers for Disease Control and Prevention & Division of Viral Diseases. CDC 2019- Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. Available at: https://www.fda.gov/media/134922/download.

- 3. Chu, D.K.W., et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. Clin Chem (2020).
- 4. Corman, V.M., et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.

Euro Surveill 25 (2020).

- 5. Susan Sefers and Jonathan E. Schmitz (2013). Molecular Contamination and Amplification Product Inactivation. Tang, Y-W and Stratton CW (Eds). Advanced techniques in diagnostic microbiology. (pp. 505-525).
- 6. Ioanna Smyrlaki et al. Massive and rapid COVID-19 testing is feasible by extraction free SARS-CoV-2 RT-qPCR. BioRxiv. Available at: https://doi.org/10.1101/2020.04.17. 20067348
- 7. R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: http://www.R-project.org/.
- 8. Bruce, E. A. et al. Direct RT-qPCR detection of SARSCOV-2 RNA from patient nasopharyngeal swabs without an RNA extraction step. bioRxiv 2020.03.20.001008 (2020) doi:10.1101/2020.03.20.001008.
- 9. Xueliang Wang et al. Limits of Detection of 6 Approved RT–PCR Kits for the Novel SARS Coronavirus-2 (SARS-CoV-2). Clinical Chemistry 0:0 1–2 (2020).
- 10. WHO. Scientific Brief: Criteria for releasing COVID-19 patients from isolation. Available at: https://www.who.int/news-room/commentaries/detail/criteria-for-releasing-covid-19-patients-from-isolation